Rankings
▼
Calendar
▼
CTOR Q1 2023 Earnings Report — Citius Oncology, Inc. Revenue & Financial Results | Market Cap Arena
Citius Oncology, Inc.
CTOR
Q1 2023 Earnings
Reported December 31, 2022
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
Q1 2023
Q4 2022
Q1 2022
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$2M
-$7M
—
77.0%
—
EPS (Diluted)
$0.04
$-0.00
—
42300.0%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$934.3K
Selling & Marketing
$0
General & Administrative
$774.2K
SG&A Expenses
$774.2K
Other Expenses
$0
Operating Expenses
$2M
Cost & Expenses
$2M
OPERATING INCOME
-$2M
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$2M
Income Tax Expense
$144.0K
Net Income from Continuing Ops
-$2M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$2M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$2M
D&A
$2M
EBIT
-$2M
EBITDA
$0
EPS
$0
EPS Diluted
$0
marketcaparena.com
← Q4 2022
CTOR Overview
Q2 2023 →